214 related articles for article (PubMed ID: 36409994)
1. Cystic Fibrosis Screen Positive, Inconclusive Diagnosis Genotypes in People with Cystic Fibrosis from the U.S. Patient Registry.
Salinas DB; Wee CP; Bailey B; Raraigh K; Conrad D
Ann Am Thorac Soc; 2023 Apr; 20(4):523-531. PubMed ID: 36409994
[No Abstract] [Full Text] [Related]
2. Benign outcome among positive cystic fibrosis newborn screen children with non-CF-causing variants.
Salinas DB; Sosnay PR; Azen C; Young S; Raraigh KS; Keens TG; Kharrazi M
J Cyst Fibros; 2015 Nov; 14(6):714-9. PubMed ID: 25824995
[TBL] [Abstract][Full Text] [Related]
3. Risk of CFTR-related disorders and cystic fibrosis in an Italian cohort of CRMS/CFSPID subjects in preschool and school age.
Fevola C; Dolce D; Tosco A; Padoan R; Daccò V; Claut L; Schgor T; Sepe A; Timpano S; Fabrizzi B; Piccinini P; Taccetti G; Bonomi P; Terlizzi V
Eur J Pediatr; 2024 Feb; 183(2):929-938. PubMed ID: 38054992
[TBL] [Abstract][Full Text] [Related]
4. Benign and Deleterious Cystic Fibrosis Transmembrane Conductance Regulator Mutations Identified by Sequencing in Positive Cystic Fibrosis Newborn Screen Children from California.
Salinas DB; Sosnay PR; Azen C; Young S; Raraigh KS; Keens TG; Kharrazi M
PLoS One; 2016; 11(5):e0155624. PubMed ID: 27214204
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Cystic Fibrosis Screening-Positive Infants With Inconclusive Diagnosis at School Age.
Gonska T; Keenan K; Au J; Dupuis A; Chilvers MA; Burgess C; Bjornson C; Fairservice L; Brusky J; Kherani T; Jober A; Kosteniuk L; Price A; Itterman J; Morgan L; Mateos-Corral D; Hughes D; Donnelly C; Smith MJ; Iqbal S; Arpin J; Reisman J; Hammel J; van Wylick R; Derynck M; Henderson N; Solomon M; Ratjen F
Pediatrics; 2021 Dec; 148(6):. PubMed ID: 34814176
[TBL] [Abstract][Full Text] [Related]
6. Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening.
Munck A; Bourmaud A; Bellon G; Picq P; Farrell PM;
Pediatr Pulmonol; 2020 Apr; 55(4):918-928. PubMed ID: 31916691
[TBL] [Abstract][Full Text] [Related]
7. Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis.
Ren CL; Borowitz DS; Gonska T; Howenstine MS; Levy H; Massie J; Milla C; Munck A; Southern KW
J Pediatr; 2017 Feb; 181S():S45-S51.e1. PubMed ID: 28129812
[TBL] [Abstract][Full Text] [Related]
8. The diagnosis of cystic fibrosis.
De Boeck K; Vermeulen F; Dupont L
Presse Med; 2017 Jun; 46(6 Pt 2):e97-e108. PubMed ID: 28576637
[TBL] [Abstract][Full Text] [Related]
9. Gradual increase in sweat chloride concentration is associated with a higher risk of CRMS/CFSPID to CF reclassification.
Salinas DB; Ginsburg DK; Wee CP; Saeed MM; Brewington JJ
Pediatr Pulmonol; 2023 Apr; 58(4):1074-1084. PubMed ID: 36582049
[TBL] [Abstract][Full Text] [Related]
10. A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres.
Terlizzi V; Claut L; Tosco A; Colombo C; Raia V; Fabrizzi B; Lucarelli M; Angeloni A; Cimino G; Castaldo A; Marsiglio L; Timpano S; Cirilli N; Moroni L; Festini F; Piccinini P; Zavataro L; Bonomi P; Taccetti G; Southern KW; Padoan R
J Cyst Fibros; 2021 Sep; 20(5):828-834. PubMed ID: 33883100
[TBL] [Abstract][Full Text] [Related]
11. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
12. Cystic Fibrosis screen positive, inconclusive diagnosis (CFSPID) to Cystic Fibrosis: Detecting disease with serial assessments.
Manzoor J; Hughes DA
Paediatr Respir Rev; 2023 Sep; 47():19-22. PubMed ID: 37365112
[TBL] [Abstract][Full Text] [Related]
13. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis.
Sermet-Gaudelus I; Girodon E; Roussel D; Deneuville E; Bui S; Huet F; Guillot M; Aboutaam R; Renouil M; Munck A; des Georges M; Iron A; Thauvin-Robinet C; Fajac I; Lenoir G; Roussey M; Edelman A
Thorax; 2010 Jun; 65(6):539-44. PubMed ID: 20522854
[TBL] [Abstract][Full Text] [Related]
14. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
[TBL] [Abstract][Full Text] [Related]
15. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.
De Boeck K; Weren M; Proesmans M; Kerem E
Pediatrics; 2005 Apr; 115(4):e463-9. PubMed ID: 15772171
[TBL] [Abstract][Full Text] [Related]
16. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
17. Inconclusive diagnosis of cystic fibrosis after newborn screening.
Ooi CY; Castellani C; Keenan K; Avolio J; Volpi S; Boland M; Kovesi T; Bjornson C; Chilvers MA; Morgan L; van Wylick R; Kent S; Price A; Solomon M; Tam K; Taylor L; Malitt KA; Ratjen F; Durie PR; Gonska T
Pediatrics; 2015 Jun; 135(6):e1377-85. PubMed ID: 25963003
[TBL] [Abstract][Full Text] [Related]
18. Newborn blood spot screening for cystic fibrosis with a four-step screening strategy in the Netherlands.
Dankert-Roelse JE; Bouva MJ; Jakobs BS; Janssens HM; de Winter-de Groot KM; Schönbeck Y; Gille JJP; Gulmans VAM; Verschoof-Puite RK; Schielen PCJI; Verkerk PH
J Cyst Fibros; 2019 Jan; 18(1):54-63. PubMed ID: 30146269
[TBL] [Abstract][Full Text] [Related]
19. Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses.
Sosnay PR; Salinas DB; White TB; Ren CL; Farrell PM; Raraigh KS; Girodon E; Castellani C
J Pediatr; 2017 Feb; 181S():S27-S32.e1. PubMed ID: 28129809
[TBL] [Abstract][Full Text] [Related]
20. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
